Racemic drug resolution: a comprehensive guide
The human body is amazingly chirally selective, and consequently enantiopure drugs are essential for treating disease. Nearly 50% of drugs are chiral wherein pharmacological activity resides with the eutomer (pharmacologically active enantiomer) whereas the distomer (inactive/less potent/equally pot...
Saved in:
| Published in | Analytical methods Vol. 8; no. 42; pp. 7567 - 7586 |
|---|---|
| Main Author | |
| Format | Journal Article |
| Language | English |
| Published |
01.01.2016
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Summary: | The human body is amazingly chirally selective, and consequently enantiopure drugs are essential for treating disease. Nearly 50% of drugs are chiral wherein pharmacological activity resides with the eutomer (pharmacologically active enantiomer) whereas the distomer (inactive/less potent/equally potent/different pharmacological activity/toxic enantiomer) metabolizes by a different pathway and creates unnecessary burden on the body. A teratogenic (toxic) isomer in a racemic drug creates side-effects, genetic diseases, or may cause death in the case of high dosage. Nowadays, market approval of enantiopure drugs has increased exponentially whereas it has tremendously decreased for racemic and achiral drugs. An expensive process is the main drawback in obtaining enantiopure drugs. Different methods such as chromatography, spectroscopy, and thermal analysis are available for optical purity determination. However, only a few chromatographic methods are useful on an industrial scale. In the present review, racemic resolution and optical purity determination methods are discussed with examples. In addition to this, eutomers and distomers of different drugs containing a single chiral center are also reported.
The human body is amazingly chirally selective, and consequently enantiopure drugs are essential for treating disease. Nowadays, market approval of enantiopure drugs has increased exponentially whereas it has tremendously decreased for racemic and achiral drugs. |
|---|---|
| Bibliography: | Dr Sachin Mane obtained his PhD in Chemistry from the Polymer Science and Engineering Division, National Chemical Laboratory, Pune, India in 2016. He is currently working as an Institute Postdoctorate at the Indian Institute of Technology Bombay, Mumbai, India. Currently he has received the Postdoctorate fellowship from the Science and Engineering Research Board (SERB-Overseas), India for postdoc study in Nanjing Tech University, Nanjing, China. His research interests include porous, functional and crosslink polymers for continuous flow synthesis, catalytic applications, carbon dioxide capture, racemic drug resolution, metal extraction and drug delivery applications. He is also interested in the design and synthesis of thermotropic/lyotropic liquid crystalline polymers. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ISSN: | 1759-9660 1759-9679 |
| DOI: | 10.1039/c6ay02015a |